Hubble Therapeutics LLC has successfully closed a $7.3 million series A funding round to support progression of its lead candidate, HUB-101, into clinical trials.
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development of its novel histone deacetylase-6 (HDAC6) inhibitors.
Hillstar Bio came out of stealth mode, announcing a $67 million series A financing round with investors including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S and Lifearc Ventures.
Hillstar Bio has successfully closed a $67 million series A financing round to support its development of next-generation precision immunology therapies for autoimmune diseases. The company’s approach selectively targets and depletes pathogenic immune cells with the potential to reset the immune system.
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development of its novel histone deacetylase-6 (HDAC6) inhibitors.
RSS
